



Editorial: Biomedical advances in ultrasound-mediated drug/ molecule delivery

Agata A Exner, Jean-Michel Escoffre

► To cite this version:

Agata A Exner, Jean-Michel Escoffre. Editorial: Biomedical advances in ultrasound-mediated drug/ molecule delivery. 2022, 10.3389/fphar.2022.974921 . inserm-03749549

HAL Id: inserm-03749549

<https://inserm.hal.science/inserm-03749549>

Submitted on 11 Aug 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



OPEN ACCESS

EDITED AND REVIEWED BY
Alastair George Stewart,
The University of Melbourne, Australia

*CORRESPONDENCE
Jean-Michel Escoffre,
jean-michel.escoffre@univ-tours.fr

SPECIALTY SECTION
This article was submitted to
Translational Pharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 21 June 2022

ACCEPTED 11 July 2022

PUBLISHED 11 August 2022

CITATION

Exner AA and Escoffre J-M (2022),
Editorial: Biomedical advances in
ultrasound-mediated drug/
molecule delivery.
Front. Pharmacol. 13:974921.
doi: 10.3389/fphar.2022.974921

COPYRIGHT

© 2022 Exner and Escoffre. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Editorial: Biomedical advances in ultrasound-mediated drug/molecule delivery

Agata A. Exner¹ and Jean-Michel Escoffre^{2*}

¹Case Western Reserve University, Cleveland, OH, United States, ²UMR 1253, iBrain, Université de Tours, Inserm, Tours, France

KEYWORDS

therapeutic ultrasound, biological barriers, drug delivery, pharmacokinetics, pharmacodynamics

Editorial on the Research Topic

[Biomedical advances in ultrasound-mediated drug/molecule delivery](#)

Despite the increasing number of innovative drugs and the development of novel targeted methods, therapeutic advances remain modest for many prevalent and costly diseases including neurodegenerative disorders, cancers, and cardiovascular diseases among others. One of the major therapeutic hurdles is the presence of biological barriers in multiple organs (e.g., endothelial and epithelial barriers, plasma membrane, interstitial pressure, detoxification processes, etc.). While they sustain organ/tissue homeostasis in physiological conditions, these barriers substantially impede the delivery of a vast majority of therapeutic molecules (e.g., chemotherapeutics, antibiotics, nucleic acids, antibodies, etc.) in diseased tissues, thus reducing their bioavailability and therapeutic effect. This challenge narrows the landscape of usable therapeutic molecules and drastically influences the design of many therapeutic protocols. Therefore, crossing of biological barriers in drug studies is undoubtedly a source of major RD investments in academia and pharmaceutical industry.

For over 2 decades, therapeutic ultrasound (US) applications facilitating gene/drug delivery have been widely investigated, with some approaches being on the brink of reaching the bedside. Among these, using US-responsive particles injected systemically, e.g., microbubbles, to facilitate US-mediated, crossing of biological barriers has been shown to: 1) be applicable in a standardized and non-invasive fashion in laboratory animals and human subjects, and 2) render therapeutically-achievable drug/molecule biodistribution, supporting the clinical translatability of this modality. While these advances foresee a “blue sky” in the field, like in many medical specialties, the translation gap remains challenging to evaluate. One may ask - to *what extent is a successful pre-clinical study predictive of the outcome of its clinical counterpart?* Before devising a clinical study, it is essential to boost chances of clinical success by conducting impactful *in-vitro* and preclinical studies that can inform clinical trial design and enable technology translation.

This Research Topic promotes four original contributions in the fields of bactericidal therapy, alopecia, cancer and gene therapy from 27 authors: three from Asia and one from Europe. All findings reported in the Research Topic had 4,912 views on 1 June 2022 (Source: Frontiers in Pharmacology).

Bacterial infection and inflammation are strongly involved in the pathogenesis of androgenic alopecia (Sakr et al., 2013). Minoxidil and lysozyme are both potent bioactive agents that were evidenced to display bactericide properties and to promote the enhancement of hair follicle growth (Springer et al., 2003; Yamasaki and Gallo, 2008); their codelivery requires a novel encapsulation formulation. In this issue, Liao and others report the design and the *in-vitro* and *in-vivo* validation of a new type of minoxidil-coated lysozyme-shelled microbubble (MB) for inhibiting bacterial infections and for enhancing hair follicle growth (Liao et al.). The authors showed an increased penetration of minoxidil and lysozyme into the skin and an enhancement of hair growth compared to minoxidil treatment alone.

The exploitation of a clinical US scanner and clinically-approved microbubbles for enhanced drug delivery is increasing interest to facilitate the clinical translation of US-mediated drug delivery methods (Lammertink et al., 2015). Here, two articles describe that clinical US scanner with their respective probes (Philips iU22 with S5-1 probe; Canon Aplio XG SSA-790 with PLT-704SBT probe) and clinically-approved MBs (SonoVue; Sonazoid) can safely and effectively enhance the drug concentration (bleomycin; pirarubicin) *in-vitro* (De Maar et al.) and *in-vivo* (Sasaki et al.).

Recently, nanobubbles (NBs) have attracted attention as an alternative option to MBs for US-mediated drug and gene delivery (Exner and Kolios, 2021). In this Research Topic, Kida et al. report the influence of NB size distribution on US-mediated plasmid DNA (pDNA) and messenger RNA (mRNA) delivery. They demonstrated that NBs with size greater than 200 nm resulted in higher transfection efficiency *in vitro*. We look forward to consulting future results on the underlying mechanism for this method and on its efficacy to deliver therapeutic pDNA and mRNA.

In conclusion, this Research Topic of relevant contributions shedding the light on the biomedical advances in US-mediated

drug delivery. Altogether these results show the drive 1) to develop this approach for new clinical applications (bacterial infections, gene therapy) and 2) to transfer it to the clinic. But they also highlight the need to develop new US-sensitive drug carriers (drug-loaded MBs, NBs) in order to answer clinical needs.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Acknowledgments

The editors thank Marc Derieppe (Prinses Máxima Centrum, Utrecht, the Netherlands), who initiated this Research Topic before leaving for new professional adventures, all authors for their original contributions, all the reviewers for their fruitful feedbacks.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Exner, A. A., and Kolios, M. C. (2021). Bursting microbubbles: How nanobubble contrast agents can enable the future of medical ultrasound molecular imaging and image-guided therapy. *Curr. Opin. Colloid Interface Sci.* 54, 101463. doi:10.1016/j.cocis.2021.101463
- Lammertink, B. H. A., Bos, C., Deckers, R., Storm, G., Moonen, C. T. W., Escoffre, J. M., et al. (2015). Sonochemotherapy: From bench to bedside. *Front. Pharmacol.* 6, 138. doi:10.3389/fphar.2015.00138
- Sakr, F. M., Gado, A. M., Mohammed, H. R., and Adam, A. N. N. (2013). Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: A pilot study. *Drug Des. devel. Ther.* 7, 413–423. doi:10.2147/DDDT.S43481
- Springer, K., Brown, M., and Stullberg, D. L. (2003). Common hair loss disorders. *Am. Fam. Physician* 68 (1), 93–102.
- Yamasaki, K., and Gallo, R. L. (2008). Antimicrobial peptides in human skin disease. *Eur. J. Dermatol.* 18 (1), 11–21. doi:10.1684/ejd.2008.0304